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OmiHtrA2 is a highly conserved mammalian serine protease that belongs to the HtrA 
family of proteins.  Omi shares homology with the bacterially expressed heat shock protease 
HtrA, which functions as a protease at higher temperatures and a chaperone at lower 
temperatures.  Additionally, Omi shares sequence similarity with the mammalian homologs 
L56/HtrA1 and PRSP/HtrA3.  Omi was first isolated as an interacting protein of Mxi2, an 
alternatively spliced form of the p38 stress-activated kinase, using a modified yeast two-hybrid 
system.  Omi localizes in the mitochondria and in response to apoptotic stimuli the mature form 
of this protein translocates to the cytoplasm.   In the cytoplasm Omi participates in both the 
caspase-dependent as well as caspase-independent apoptosis.  Additionally, recent studies 
suggest that Omi may have another unique function, maintaining mitochondrial homeostasis 
within the mitochondria.  In an effort to further elucidate the function of Omi, a yeast two-hybrid 
screening was performed to isolate novel interacting proteins.  This screening identified a novel 
protein (HOPS), as a specific interactor of Omi.  The predicted amino acid sequence of this 
protein does not provide any information about its potential function in mammalian cells.  
However, experiments show that HOPS is cleaved in vitro by Omi.  Furthermore, in response to 
apoptotic stimuli, HOPS is also degraded in vivo.  This study suggests that HOPS could be a 
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CHAPTER ONE: INTRODUCTION AND REVIEW OF LITERATURE 
1.1 Cell Death-Apoptosis and Necrosis 
Cell death is imperative in the development of a healthy organism, as well as in the 
maintenance of homeostasis that is necessary for life.  One major type of cell death, apoptosis, 
plays an essential role in this delicate equilibrium.  The average adult sheds 10 billion cells each 
day to preserve this balance (1).  Apoptosis, or “programmed cell death”, allows an organism to 
control the number of cells within a tissue, while guarding from the harmful effects of unwanted 
cells.  It is this form of programmed cell death that aids in regulating portions of the immune 
system, contouring the shape of fingers from webbing during fetal development, as well as 
eliminating cells that are superfluous, damaged, or infected (2, 3). 
John Kerr and colleagues first defined apoptosis, in 1972, as a distinct process of cell 
death, differing from necrosis (4).  This was followed by an important observation in the 
nematode, Caenorhabditis elegans, that of 1,090 cells exactly 131 are lost through the process of 
programmed cell death to form the adult worm (5).  Pro-apoptotic proteins were later identified 
as major players in this pathway leading to cell death in the nematode.  Examples of such 
proteins include the products of the nematode genes ced-3 and ced-4.  Each of these gene 
products share homology with genes in other species, suggesting that the mechanism of 
apoptosis is highly conserved (6, 7). 
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Cell death by apoptosis is most frequently characterized by morphological changes 
within the cell.  There are four basic phases of apoptosis that include initiation, execution, 
disintegration, and elimination (6.).  Some noted features are shrinkage of the cell, DNA 
fragmentation to approximately 200 base pairs, blebbing of the cell membrane, condensation of 
chromatin, and the formation of apoptotic bodies (Figure 1) (8).  Since the cells are ultimately 
phagocytized, the lytic contents of the cells are not released into the surrounding environment; 
consequently this form of cell death is devoid of inflammation (6).   
Due to the important role of apoptosis as a regulator of cellular homeostasis, modification 
of this process can have deleterious effects on an organism.  Insufficient apoptosis correlates 
with the accumulation of unwanted or damaged cells, which may ultimately result in malignancy 
or autoimmune diseases (1, 9, 10).  In contrast, excessive apoptosis has been associated with a 
variety of maladies, for example, Alzheimer’s and Parkinson’s diseases (8). 
In the past a clear line could be drawn between apoptosis and the other major type of cell 
death, necrosis.  These parameters allowed necrosis to be characterized by swelling of the cell, 
rupturing of the plasma membrane, and release of cellular contents into the surrounding 
environment leading to inflammation (Figure 1).  However, current research suggests that 
although morphologically different, at times the two routes leading to cell death can overlap and 
may even share common pathways (11). In various diseases including cancer, autoimmune 
diseases, and neurodegeneration, apoptosis can occur in association with necrosis (12).  This 
overlap is illustrated in another type of cell death, “aponecrosis”, that is considered an 


















Figure 1: Morphological Changes Observed in Cell Death 
On the right, the figure depicts the changes seen during apoptosis.  Upon apoptotic stimuli, the 
cell begins to condense; this is followed by DNA fragmentation. The cell breaks off into smaller 
membrane-bound “apoptotic bodies”, that will eventually be phagocytized. In contrast, the left 
portion of the figure represents the morphological changes seen during necrosis.  These include 
cell swelling that leads to the lysis of the cell, and the release of intracellular components into the 




1.2 Caspases-Mediators of Apoptosis 
The role of caspases in programmed cell death was elucidated when homology was 
observed between the cell death genes of the nematode, C. elegans, and mammals (14).  Much of 
the changes that can be observed within an apoptotic cell are the result of these homologous gene 
products, known as caspases, which cleave substrates after an aspartate residue. Currently, 
fourteen distinct members of this family of cysteine proteases have been identified (15). 
Within this family of caspases, those involved in the apoptotic pathway are subdivided 
into two groups, the initiator and the effector caspases.  The initiator caspases, also termed 
“upstream caspases”, include caspase-8, caspase-9, and caspase-10.  Effector or “downstream” 
caspases are comprised of caspases –3, -6, -7.  In response to an apoptotic signal, initiator 
caspases function to launch the apoptotic cascade by activating downstream effector caspases 
which break down the cell (16). 
The specificity of each caspase for a substrate is determined by a sequence of four amino 
acids that is upstream to the cleavage site of the substrate.  This cleavage may either activate the 
substrate or render it inactive so that it may no longer properly function.  Some substrates of 
downstream caspases include cytoskeletal proteins, inhibitors of endonucleases, or proteins 
involved in signaling or repair.  Ultimately resulting in the biological and morphological changes 
seen in cell death (17). 
Caspases are made up of three domains: a small subunit, a large subunit, and an N-
terminal pro-domain.  Initially, caspases are expressed within the cell as zymogens, or pro-
caspases, and remain inactive until each domain is separated by proteolytic cleavage.  A 
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heterodimeric association of the large and small subunits, which later join to form a tetramer, 
follows this cleavage (16).  Initiator caspases have a longer pro-domain that includes a site for 
protein-protein interaction.  For caspase-8 and caspase–10 this domain is labeled DED, or death 
effector domain.  The remaining initiator caspases including caspase-9 contain a caspase 
activation and recruitment domain (CARD).  Both domains, through their interaction with other 
signaling proteins, take part in controlling this complex cascade leading to programmed cell 
death (7, 18). 
 
 
1.3 Pathways of Cell Death 
At present, two major mechanisms of apoptosis regulation have been defined.  They are 
the caspase dependent and the caspase-independent pathways (Figure 2).  The caspase-dependent 
pathway is composed of two independent sub-pathways (19).  One, the extrinsic pathway, 
involves the initiation of death receptor molecules on the surface of the cell.  Second, the 
intrinsic pathway, is mediated primarily through the mitochondria by various apoptotic signals 
(10).  Although each pathway originates from a different location within the cell, the two 
converge with the activation of downstream effector caspases that result in the morphological 
changes seen in an apoptotic cell.  The caspase independent pathway does not involve the 
activation of caspases, but instead executes cell death through other proteins.  For example, 
apoptosis inducing factor (AIF), is released from the mitochondria, translocates to the nucleus 
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and induces apoptosis.  Proteins such as Endonuclease G, granzymes, and calpains have also 
been shown to behave as proteases (7, 18, 20, 21). 
The extrinsic pathway propagates the death signal following the binding of a ligand to a 
member of the tumor necrosis factor (TNF) superfamily of death receptors, located on the 
surface of the cell.  Six various death receptors have been identified and include: CD95, TNF-
R1, DR3, TRAIL-R1, TRAIL-R2, and DR6 (22).  Each of these transmembrane death receptors 
contain a death domain located on the intracellular surface of the cell.  This domain functions in 
binding to signaling molecules involved in the apoptotic pathway.  Once a ligand binds to its 
respective receptor, the receptor trimerizes and then recruits various adaptor molecules that bind 
to the death domain.  This complex is referred to as the death inducing signaling complex 
(DISC) (23).  The adaptor molecules contain a death effector domain at their amino terminus that 
intimately interacts with initiator procaspase-8 leading to its activation.  This signal is then 
transmitted to downstream caspases, resulting in apoptosis of the cell (6). 
The intrinsic pathway is activated in response to various stimuli often referred to as 
“cellular stress”.  These stressors, which include among others: ionizing radiation, cytotoxic 
drugs, and free radicals, are believed to cause a change in the mitochondrial membrane potential.  
This alteration in the membrane integrity leads to the release of a variety of pro-apoptotic 
proteins into the cytosol.  One such protein, cytochrome c, forms a complex with the adaptor 
protein, Apaf-1, and ATP (24).  This complex referred to as the apoptosome, then recruits and 
activates procaspase-9 (19, 20).  Once active, caspase-9 proteolytically activates effector 
caspases, including procaspase-3, generating the morphological and physical changes in an 
apoptotic cell (16, 20).  
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Both the intrinsic and extrinsic pathway interconnects with the pro-apoptotic protein Bid.  
Bid is a member of the BH3 only, Bcl-2 family of proteins (6).  This protein shares homology 
with the BH3 domain of the founding molecule of this family, Bcl-2 (25).  Bid is processed into 
tBid by caspase-8 of the extrinsic pathway. Once truncated, tBid translocates to the mitochondria 
where it may interact with other proapoptotic proteins, such as Bax and Bak (26).  Though the 
mechanism is not yet completely clear it is known that truncated Bid ultimately promotes the 
release of cytochrome c from the mitochondria (22). 
 
 
Figure 2: Pathways of Apoptosis 
This figure is a schematic representation of the extrinsic, intrinsic, and caspase-independent cell 
death pathways.  The extrinsic pathway is activated through the stimulation of death receptors on 
the surface of the cell.  While, the intrinsic pathway is activated through various cellular 
“stressors” (20).  Both pathways converge at the mitochondria, where the release of a variety of 
apoptotic proteins occurs. Among these is cytochrome c, which binds to Apaf-1, and caspase-9 
forming the apoptosome.  Additionally, Omi/HtrA2 and Smac//DIABLO are able to bind to 
XIAP, an endogenous inhibitor of caspases, thereby alleviating the inhibition of caspases and 
promoting apoptosis (7).  
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1.4 Preventing Apoptosis-Inhibitors of Caspases 
The proteolytic cleavage of proteins by caspases is an irreversible event, therefore, it is 
essential that not only the activation but also the activity of these proteases be tightly regulated 
within the cell.  Inhibitors of apoptosis (IAPs) are a class of proteins that function by binding to 
and inhibiting caspases so that healthy cells may survive (20). 
IAPs were originally identified in baculoviruses where they functioned to inhibit 
apoptosis in host cells during viral infection.  Since then the evolutionarily conserved IAPs have 
been found in viruses, yeast, flies, and mammals (8).  Two motifs have been recognized as part 
of the structure of IAPs.  All IAPs contain anywhere from one to three baculovirus IAP repeat 
domains (BIR), which are made up of approximately 70 amino acid residues.  The BIR domain 
seems to be mandatory for the anti-apoptotic property of these proteins, and in some cases has 
been found to directly interact with caspases.  Additionally, a RING finger domain can be found 
at the carboxy terminus of some inhibitors of apoptosis.  Proteins that contain this RING domain 
are able to ubiquitinate other proteins in addition to initiating their own degradation (18, 27).   
Currently, there are eight IAPs that have been identified: XIAP, c-IAP1, c-IAP2, NAIP, 
Survivin, Bruce, Livin, and ILP-2.  These inhibitors of apoptosis are able to bind to either the 
pro-caspase or active form of caspases to inhibit their activity thereby preventing caspase-





1.5 Inhibitors of IAPs: Smac and Omi 
In order for a cell to undergo the process of programmed cell death, the inhibition of 
caspases by IAPs must be terminated. Three proteins, Reaper, Hid, and Grim, originally 
identified in the insect Drosophila melanogaster perform this function (28). Recently, two other 
proteins, Smac/Diablo and Omi/HtrA2, were identified as mammalian homologs of these 
proteins. Omi is the focus of this study.   
Both Smac/DIABLO and Omi/HtrA2 are nuclear encoded mitochondrial proteins that 
share an amino terminal sequence homology with the Reaper, Hid, and Grim proteins (29). This 
homologous sequence is referred to as the IAP binding motif (IBM).  This sequence allows these 
proteins to bind to IAPs, permiting their release from caspases consequently enabling apoptosis 
to take place (7). 
Smac (Second Mitochondrial Activator of Caspases) or DIABLO (Direct IAP Binding 
Protein with Low pI) is initially made as a 29 kDa precursor protein.  This precursor translocates 
to the mitochondria where its mitochondrial localization signal is removed, generating the 
mature protein of 23 kDa. Upon apoptotic stimuli mature Smac/DIABLO is then released from 
the intermembrane space of the mitochondria into the cytosol, where it is able to bind to and 
sequester IAPs.  Smac/DIABLO has been shown to bind to XIAP, c-IAP1 and c-IAP2, and 




1.6 Characterization of Omi 
Omi/HtrA2, was originally isolated as an interactor of Mxi2, the alternatively spliced 
form of the p38 stress activated kinase.  Omi is a serine protease containing a high homology to 
the bacterial HtrA heat shock protease (31).  The HtrA protein functions at higher temperatures 
as a protease and at lower temperatures as a chaperone. The Htr, or high temperature 
requirement, family of serine proteases is highly conserved from bacteria to humans (9).  Omi is 
ubiquitously expressed, while the alternatively spliced form, D-Omi, is expressed only in the 
kidneys, thyroid, and colon (32).  In healthy human cells Omi is restricted to the intermembrane 
space of the mitchondria, however, upon apoptotic stimuli it is released into the cytosol. 
Furthermore, the protease seems to be up-regulated during heat shock, ischemia or reperfusion, 
and endoplasmic reticulum stress (31). 
 Omi shares some characteristics with Smac/DIABLO but still maintains separate 
functions.  Omi/HtrA2, like Smac/DIABLO, is known for its ability to inhibit IAPs, however, in 
this case it is through irreversible cleavage.  In a similar fashion to Smac/DIABLO, Omi/HtrA2 
is translocated to the mitochondria, where the protein is processed from the 50 kDa precursor to 
the 36 kDa mature protein.  Omi/HtrA2 has been found to interact with and inhibit XIAP, 
thereby initiating apoptosis in a caspase-dependent fashion.  Upon apoptotic stimuli Omi/HtrA2 
is released into the cytosol where it binds to XIAP, however unlike Smac/DIABLO, Omi/HtRA2 
binds preferentially to the BIR3 domain of XIAP.  This interaction prevents the inhibitor from 
binding to caspase-9 thereby averting the activation of downstream effector caspases –3, -6, and 
–7 (29)  Additionally, this protein has been shown to interact with cIAP1 and cIAP2.  In contrast 
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to Smac/DIABLO, Omi/HtrA2 does not bind to Survivin.  Furthermore, Omi has also been found 
to induce cell death through a caspase-independent mechanism, observed only when Omi is 
overexpressed in cells (30, 31). 
Omi/HtrA2 shares homology with two other known proteases, HtrA1/L56 and 
HtrA3/PRSP (pregnancy related serine protease).  HtrA1/L56 has been shown to be in higher 
concentration in osteoarthritic tissue, and at lower levels in fibroblasts transformed with SV40 
virus.  Both HtrA1 and HtrA3 are significantly expressed in placental tissue (33). While HtrA1 
and HtrA3 share high functional homology, Omi is limited to having homology with these 
proteins only at the carboxy terminus of the protein.  The amino terminal end of Omi contains a 
regulatory domain that is not present in the other serine proteases.  Interestingly, each of the 
three proteases contains a highly conserved proteolytic domain.  Although the function of HtrA1 
and HtRA3 is not yet elucidated, the similarity between these two proteins suggests that they 








Figure 3: Sequence Comparison of Human HtrA Proteins and Homolog in E. coli 
The alignment shows the similarities and differences between the three known HtrA family 
proteins as well as that of E. coli.  Catalytic triad residues are boxed in red and the secondary 
















Figure 4: Domain Comparison of the Human HtrA Family 
The diagram shows the differences between members of the HtrA family.  HtrA1 and HtrA3 
show a high degree of similarity, both having a signaling peptide (SP), IGF-binding domain (IB), 
a Kazal domain (Kazal), a trypsin like domain (trypsin), in addition to a PDZ domain (PDZ).  In 
contrast, Omi contains an N-terminal regulatory domain instead of the SP, IB, and Kazal.  For 







1.7 Structure of Omi 
Omi/HtrA2 contains three major domains including a regulatory domain at the amino 
terminus, a centrally located catalytic domain, and a single PDZ domain at the carboxy terminus.  
Within the regulatory domain exists a mitochondrial targeting sequence (MTS), a predicted 
transmembrane region, a phosphorylation site, and a SH3 binding domain.  In addition, upstream 
to these features there is PRAXXTXXTP sequence that is repeated three times (31, 36).  The 
serine protease’s catalytic domain is comprised of three amino acids His 198, Asp 228, and Ser 
306.  This catalytic triad is folded with high similarity to that of trypsin, and is necessary for 
Omi’s protease activity.  Lastly, the PDZ domain is involved in interactions with other proteins, 
through its ability to recognize hydrophobic residues (35). 
Omi is synthesized as a 458 amino acid precursor.  Upon translocation to the 
mitochondria, 133 amino acids at the N terminus of the precursor are removed by cleavage.  This 
exposes the conserved AVPS motif present in mature Omi that recognizes and binds IAPs (29). 
The mature form of Omi is composed of 7 α helices and β strands.  Together these structures 
form the serine protease domain as well as the PDZ domain (35).   
When crystallized, the mature form of Omi/HtrA2 forms a homotrimer.  This 
trimerization generates a pyramid structure housing the IBM sequences at the top and the PDZ 
domain at the bottom.  The serine protease domain in addition to the N terminal sequences 
controls formation of this pyramid. Additionally, the formation of this structure seems to be 
imperative in the proteolytic pro-apoptotic function of Omi.  A working model, proposed by Li 
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et al, suggests that perhaps the binding of a protein to the PDZ domain, leads to a conformational 
change in the trimer, which allows access to the catalytic site of the protease (35).  
 
Figure 5: Functional Domains of Omi  
Omi contains an N-terminal regulatory domain, a catalytic domain, and a C-terminal PDZ 
domain.  The regulatory domain contains a mitochondrial targeting sequence (MTS) and three 
PRAXXXTXXP motif of unknown function.  The mature form of Omi lacks the first 133 amino 










Figure 6: Trimeric Organization of Omi 
Crystal structure analysis of Omi revealed that the active protease forms a trimer.  Each subunits 
catalytic domain mediates the arrangement of this structure.  The PDZ domain is at the base of 
the structure, while the IAP binding motif is situated at the top (35). 
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1.8 PDZ Domain of Omi 
Recognized over 10 years ago, PDZ domains were originally identified in signaling 
proteins, as regions of high sequence homology.   These domains have recently been identified 
as important protein-protein interacting regions necessary in a wide variety of proteins and 
diverse organisms.  The PDZ domain is named after the first three proteins that contained a 
similar amino acid sequence: the post-synaptic density protein PSD-95, the Drosophila 
melanogaster Discs Large protein, and Zonula occludens 1 protein Zo-1 (37, 38).  Presently, as 
many as 259 proteins within the human genome, have been suggested to contain PDZ domains 
(39). 
Approximately 90 amino acids in length, PDZ domains specialize in binding to specific 
C-terminal motifs.  These motifs are within 6 amino acids in length and require a free 
carboxylate group. Crystallographic data suggest that the binding of these C-terminal residues 
interact directly with the peptide binding groove (40). Hydrophobic in character, most PDZ 
domains select for a hydrophobic C-terminal residue (38, 41).   
PDZ domains can be divided into three main groups for classification purposes.  The 
distinction between these classes can be determined by the interaction at P0 and P-2.  In class I, 
the PDZ recognizes a serine or threonine at the P–2 position, as is the case with PSD-95.  For the 
Class II PDZ domain, a hydrophobic residue occupies the P0  and P–2 positions.  The third class 
of PDZ favors a negatively charged amino acid at P-2.  A fourth class of PDZ has been identified 
that prefers a negatively charged amino acid at the P0 position (42). 
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In contrast to this classification scheme, Omi does not fall into any of these categories of 
PDZ domains.  The binding selectivity of Omi/HtrA2 PDZ specificity has been shown to favor a 
valine or isoleucine at P0.  This amino acid is preceded by residues rich in either tyrosine, 














Figure 7: The PDZ Domain of Omi   
The PDZ domain of Omi mediates the activity of the protease.  After binding to a substrate the 
PDZ domain opens exposing the proteolytic domain (35).  
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1.9 Multiple Functions of Omi  
In order to understand the various functions of Omi it might be necessary to identify all 
the physiological substrates of this protease as well as any other interacting proteins that could 
regulate its function. To date, Omi has been identified as an active participant in both caspase-
dependent and caspase-independent cell death (44).  Additionally, Omi has been suggested to 
have a unique housekeeping role in mitochondria (45).   
Most of the studies published on Omi deal with its role in the caspase-dependent pathway 
of apoptosis.  Omi is now known to activate caspase-dependent cell death by blocking and 
removing inhibitors of apoptosis proteins (IAPs). This function of Omi is carried out via two 
distinct mechanisms in the cytoplasm.  One mechanism involves direct binding of Omi to IAPs 
which disrupts their association with active caspases (46). In the second mechanism, Omi is able 
to degrade and irreversibly remove IAPs.  Omi does this by using its proteolytic activity after 
binding to the inhibitors(29, 36, 44, 47, 48).  Inactivation of IAPs, in turn, leads to caspase-9 
activation and eventually to apoptosis.  The interaction of Omi with IAPs is mediated through the 
N-terminal AVPS of the mature Omi protein (28, 44).  This AVPS motif is also found in all 
known IAP interacting proteins including Drosophila homologs.  
 Furthermore, Omi is involved in the caspase-independent pathway of cell death and is 
able to induce an “atypical form” of apoptosis (28, 44).  This is independent of its AVPS motif, 
and instead relies entirely on its ability to act as a protease.  This form of cell death is observed 
in Omi proteins lacking the exposed AVPS motif at their N-terminus but it is not seen in serine-
protease inactive mutants (28, 44).  
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Lastly, Omi has been identified as a mediator of homeostasis within the mitochondria 
under normal physiological conditions.  In Mnd2 mutant mice, a missense mutation resulting in a 
Ser276Cys greatly reduces the protease activity of Omi/HtrA2 without affecting its protein levels 
or sub-cellular localization.  This suggests that the function of Omi in mitochondria may involve 
the cleavage of specific substrates (45).  These mice display signs of muscle wasting, 
neurodegeneration, and death by 40 days of age.  The fact that these knockout mice show a 
neurodegenerative phenotype, suggests that perhaps a primary function of Omi, at least in mice, 
may lie within the mitochondria (45).  This feature would concur with other pro-apoptotic 
proteins, such as cytochrome c and endonuclease G, that also have unique mundane functions in 













CHAPTER TWO: MATERIALS AND METHODS 
2.1 Construction of LexA- OmiCAT and LexA-HtrA1/L56 Baits 
2.1a Polymerase Chain Reaction 
The following primers were used in the PCR reaction for the cloning of the catalytic 
domain of Omi (amino acids 134-340) and HtrA1/L56 into pGILDA. 
Primer A 5’ OmiCAT   (MfeI): 
5’ CCC AAT TGG CCG TCC CTA GCC CGC CGC CC-3’ 
Primer B 3’ OmiCAT  (XhoI): 
5’ GGC CTC GAG TCA TCC GGA GGA GGA ATT CTT CTT-3’ 
Primer C 5’ HtrA1/L56 (MfeI): 
5’ CGC AAT TGG GGC AGG AAG ATC CCA ACA GTT TGC GC-3’ 
Primer D 3’ HtrA1/L56(XhoI): 
5’- GGC TCG AGC TAT GGG TCA ATT TCT TCG-3’ 
The restriction sites incorporated into each primer, MfeI or XhoI, are underlined.  Each 
PCR reaction was performed in 50µl volume using 20ng of template DNA, 10ρM of each 
primer, 5µl of 10X PCR buffer + Mg (Roche Diagnostics Corp.), 1.5 units of Taq polymerase 
(Roche Diagnostics Corp.), 100 µM dNTP (BD Biosciences).  The reaction is placed in a thermal 
cycler and after an initial denaturing at 95°C is passed through the following cycle 25 times: 
95°C denatur for 30s, variable annealing temperature (based on primer) for 40s, 72°C elongation 
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for a variable length of time based on size of PCR product.  This followed by a final 7 minute 
elongation step at 72°C.  Each PCR reaction is performed twice, the products of the reactions are 
then combined and precipitated.  
 
2.1b Agarose Gel Electrophoresis 
1.0 g of dried agarose (FMC BioProducts ) was added to 100ml 1X TAE (0.04M Tris-
acetate, 0.001M EDTA).  This mixture was then microwaved until all agarose had completely 
dissolved (≈ 2 minutes).  The volume was then brought up to 100ml again with water and the 
solution was allowed to cool.  Ethidium Bromide was then added to a final concentration of 
0.5µg/ml before pouring the solution into a gel tray.  After the gel solidified, the combs were 
removed.  1X TAE electrophoresis buffer was added to the electrophoresis apparatus until the 
buffer just covered the gel.   
 
2.1c Preparation of Samples for Agarose Gel Electrophoresis 
1µl of 10X gel-loading buffer made of 30% glycerol (Fisher), and 2% Orange-G (Sigma) 
in 1X TAE, was added to DNA.  The final volume was brought up to a minimum of 10µl, and 
the mixture was then loaded in a well.  DNA markers (Bioline- 40ng/µl HyperLadder or 50ng/µl 
Lambda DNA BstEII Digest) were used to estimate the size of the DNA sample.  Electrophoresis 
was performed at 50-120V, until the dye migrated the appropriate distance.  
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2.1d DNA Precipitation 
 3M Sodium Acetate, pH 5.5 was added to a DNA solution at 1/10 the volume of the 
sample.  Addditionally, 2X the sample volume of 100% ethanol –20°C was also added.  The 
sample was mixed well and stored at –20°C for a minimum of 20 minutes.  The sample was then 
centrifuged for 20 minutes at 4°C and 14000 rpm.  The supernatant was then discarded.  The 
pellet was washed in 300µl of 70% ethanol –20°C, and centrifuged again for 5 minutes.  The 
supernatant was then discarded and the pellet was dried for 10 minutes in the speed vacuum.  
The pellet was then resuspended in the appropriate volume of dH2O or Tris EDTA, pH 8.0.  
 
2.1e Restriction Enzyme Digestion 
Double stranded DNA was incubated with the appropriate amount of restriction enzyme 
and its respective buffer as suggested by the supplier.  Reactions were then incubated at 37°C for 
1-4 hrs depending on the enzyme efficiency.  For two separate digestions, DNA was precipitated 
after the first digestion and resuspended in the appropriate buffer needed for the second 
digestion.  A general protocol for a 50µl reaction is as follows:   
 
5µl     Restriction Enzyme 10X buffer 
0.5µl  BSA, 10µg/µl 
1 µl    DNA, 1µg/µl 
42µl   sterile, dH2O 
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1.5µl  Restriction Enzyme,10U/µl  
 
2.1f Ligation 
DNA concentration of 1µl of insert and 1µl of vector were estimated using gel 
electrophoresis (2.1b).  The ligation was performed using insert and plasmid DNA from gel 
purified RE digestion, an the Fast-Link DNA ligation Kit (EPICENTRE TECHNOLOGIES). In 
general a bmolar concentration of 2:1, insert:vector was used. A general protocol for a 15µl 
reaction is as follows: 
 
1.5µl  Fast-Link Ligation Buffer  
1.5µl  10mM ATP 
1 µl    Fast-Link DNA Ligase 
x µl    insert  
x µl    vector 
xµl     dH2O 
 
The mixture is then incubated at room temperature for 5 minutes.  This is followed by 
ligase deactivation at 70°C, for 15 minutes. 
To precipitate the reaction, the ligation reaction is brought to a final volume of 50µl using 
dH2O. 500µl of room temperature N-butanol is added and the solution is mixed very well. The 
sample was then centrifuged for 10 minutes at 4°C and 14000 rpm.  The supernatant was then 
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discarded.  The pellet was washed in 300µl of 70% ethanol –20°C, and centrifuged again for 5 
minutes.  The supernatant was then discarded and the pellet was dried for 10 minutes in the 
speed vacuum.  The pellet was then resuspended in the appropriate volume, ≈4µl, of dH2O.  
 
2.1g Bacterial Transformation  
The DNA to be transformed was added to 100µl of a competent bacterial cell suspension 
(either DH5α, BL21, or KC-8), mixed gently, and transferred to an electroporation cuvette (0.2 
cm electrode gap, BIO-RAD) that had been cooled to 4°C.  The cuvette was placed in the Gene 
Pulser (BioRad) that delivers a single exponential decay pulse of 2.5V.  1ml of room temperature 
LB without antibiotics was then added immediately.  The entire mixture was then transferred to a 
sterile 15ml centrifuge tube and incubated at 37°C with shaking for 45 minutes.  50µl -150µl of 
the solution was then plated on agar plates containing the appropriate antibiotic, and incubated 
overnight at 37°C. 
 
2.1h Isolation of Plasmid DNA from Bacteria: DNA Qiaprep Spin Miniprep 
Plasmid DNA was isolated using QIAprep Spin Miniprep Kit according to the 
manufacturers instuctions (QIAgen).  A single bacterial colony is chosen and grown overnight 
with shaking in 4ml LB broth with the appropriate antibiotic.  1.5ml of the bacterial culture  is 
transferred to a microcentrifuge tube and centrifuged at 14000 rpm for 2 minutes.  The 
supernatant is then aspirated.  The pelleted bacteria is resuspended in 250µl of Resuspension 
Buffer P1, stored at 4°C, containing RNase (100mg/ml).  250µl of Lysis Buffer P2 is then added, 
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and the tube is gently inverted 4-6 times. The lysate is neutralized and adjusted to high-salt 
binding conditions by adding 350µl of neutralization Buffer N3. The tube is the immediately and 
gently inverted 4-6 times and then centrifuged at 14000 rpm for 10 minutes at room temperature.  
The supernatant is then transferred to a QIAprep spin column is resting in a 2ml collection tube.  
The column is centrifuged again for 1 minute and the flow-through is discarded.  The QIAprep 
spin column is then washed using 500µl binding buffer (PB) and centrifugation at 14000 rpm, 
for 1 minute at room temperature.  The flow-through is discarded.  An additional wash is 
performed using 750µl of wash buffer (PE) and centrifugation at 14000 rpm, for 1 minute at 
room temperature.  The flow-through is discarded.  The residual wash buffer is then removed 
with an additional centrifugation for 1 minute.  The QIAprep spin column is then placed in a 
clean 1.5ml microcentrifuge tube.  By adding 50µl of Elution Buffer, EB, (10mM Tris-HCL, 
pH8.5) to the center of the column, letting stand for 1 minute, and centifuging at 14000 rpm, for 
1 minute at room temperature, the DNA is eluted.  
 
2.1i Isolation of Plasmid DNA from Bacteria: DNA-Boiling Method Miniprep 
A single bacterial colony is grown overnight with shaking in 4ml LB broth with the 
appropriate antibiotic.  The culture is then placed on ice.  1.5ml of LB containing bacteria is 
transferred to a microcentrifuge tube and centrifuged at 14000 rpm for 2 minutes.  The 
supernatant is then aspirated.  The pellet is resuspended in 300µl of filtered STET (8% Sucrose, 
5% 100X Triton, 50mM Tris-HCl pH8, and 50 mM EDTA).  25µl of 10mg/ml lyzozyme is then 
added to each sample.  The sample is vortexed briefly and placed in boiling water for 45 
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seconds.  Then the sample is centrifuged at 4°C and 14000 rpm for 15 minutes.  200µl of the 
supernatant is transferred to a new 1.5ml microcentrifuge. To this, 230µl of -20°C isopropanol is 
added and the samples are mixed well.  The tubes are placed at –20˚C for 10 min and the 
centrifuged again at 4°C and 14000 rpm for 5 minutes.  The supernatant is discarded and the 
pellet is washed with 300 µl of 70 % ethanol (-20°C).  The pellet is then dried for 10 minutes in 
the speed vacuum.  The pellet is then resuspended in dH2O or TE. 
 
2.1j DNA Sequence Analysis 
CEQ 2000 Dye Terminator Cycle Sequencing was performed using the Quick Start Kit 
(Beckman).  The reactions were performed in 0.2 ml thin walled tubes.  All reagents were kept 
on ice while the sequencing reactions were prepared. Each reaction was performed in 10 µl 
volume using the appropriate amount of template DNA (based on the size of the insert), 3ρM, 
and dH2O (to adjust the volume to 10 µl).  The components were mixed and then denatured for 2 
minutes at 95°C.  Next, 3µl of DTCS Quick Start Master Mix was added.  The reaction is placed 
in a thermal cycler and is passed through the following cycle 30 times: 96°C denature for 20s, 
50°C for 20s, 60°C for 4 minutes.  This is followed by holding at 4°C.  To this reaction 2.5µl of 
Stop Solution (1.5M NaOAc, 50mM EDTA prepared fresh by mixing equal volumes of 3M 
NaOAc and 100mM EDTA) and 1µl of 20mg/ml glycogen (Beckman Coulter) is added.  The 
reaction is then transferred to a 1.5µl microcentrifuge tube and mixed thoroughly.  To this 60µl 
of -20°C 100% ethanol is added.  This is centrifuged immediately at 4°C and 14000 rpm for at 
least 15 minutes.  This supernatant is carefully removed with a pipette and discarded.  The pellet 
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is washed with 200µl of 70% ethanol (-20°C).  The supernatant is again carefully removed with a 
pipette and discarded.  The pellet is dried in the speed vacuum for 15 minutes and resuspended in 
20 µl of Sample Loading Solution (Beckman Coulter). 
 
 
2.2 Yeast Two Hybrid Interactions 
2.2a Yeast Transformation 
50ml of appropriate medium is inoculated with a single yeast colony to be transformed, 
and grown overnight with shaking at 30°C.  The following day in a sterile 50ml Falcon tube the 
cells are harvested by centrifugation at 3800 rpm for 5 minutes.  The supernatant is then 
discarded.  The pellet is washed by resuspension in 10mL TE pH 7.5, and then centrifugation at 
3800 rpm for 5 minutes.  The supernatant is discarded.  The pellet is resuspended in 5 ml LA 
(0.1M LiOAc in TE) and transferred to a 15 ml Falcon tube.  The solution is then incubated for 
two hours at 30°C with shaking.  The cells are harvested by centrifugation at 3800 rpm for 5 
minutes.  The supernatant is discarded and the pellet is resuspended in a variable amount, usually 
≈5ml, of LA (depending on the size of the pellet).  The yeast is then separated into 300µl 
aliquots in 1.5ml microcentrifuge tubes.  Next, 1µg of DNA to be transformed is added along 
with 100µg of denatured salmon sperm DNA.  To this, 700µl of 50% PEG4000 (diluted in 
100ml of dH20) and the solution is mixed until homogeneous.  Then the yeast is incubated in a 
30°C water bath for 30 minutes.  The yeast are then moved to a 42°C water bath for 15 minutes.  
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The cells are then centrifuged for 3 minutes at 14000 rpm and the supernatant is aspirated.  The 
pellet is resuspended in 300µl of TE pH 7.5.  50µl-150µl of the solution is then plated on agar 
plates containing the appropriate selective medium, and incubated for 2 days at 30°C.  
 
2.2b Yeast Drop-Out Medium 
The yeast strain used in all experiments was auxotropic, which allowed for selection by 
using specially prepared drop out medium. A liter of drop out medium contains the following: 2g 
appropriate “drop out” powder (lacking the appropriate amino acids) (50), 6.7g Yeast Nitrogen 
Base without amino acids (Sigma) and 900 ml of sterile water (for agar plates 20g of agar (USB) 
was added as well).  The bottle was autoclaved and 2% weight-by-volume carbon source 
(Glucose or Galactose) was added.  
 
2.2c Yeast Western Blot 
3ml of yeast medium was inoculated with the yeast to be tested, the positive control, or 
the negative control, and incubated overnight at 37°C with shaking until an optical density of 
0.4-0.7 at 600nm.  The yeast was transferred to a 1.5ml microcentrifuge tube and centrifuged at 
14000 rpm for 3 minutes. The supernatant was then aspirated and the pellet was resuspended in 
50µl of 1X SDS-sample loading buffer (10% β-mercaptoethanol, 6% SDS, 20% glycerol and 
1/40 X stacking buffer and 0.2mg/ml bromophenol blue).  The samples were vortexed, placed on 
ice and then boiled for 5 min, along with a pre-stained protein marker (BioLabs).  A short spin 
was performed to remove large cell debris.  20µl of sample and 15µl of marker were loaded on a 
 28
pre-cast gradient 4-20% Tris-Glycine gel (Invitrogen).  The proteins were transferred to a PVDF 
membrane by semi-dry electrophoresis using a BioRad transfer blot.  For proper transfer PVDF 
membrane (PALL) was first activated in 50 ml methanol (CH3OH).  Gel, membrane and 2 filter 
papers were equilibrated in 250 ml transfer buffer (9.6mM Tris, 7.8mM glycine and 20 % 
CH3OH to a final pH ~9) for 5 min.  The semi-dry transfer was arranged having the soaked filter 
paper on the bottom, followed by the membrane, gel and a second sheet of filter paper on top.  
The transfer machine was run for 1 hour at 15V.  In order to block unspecific binding, the PVDF 
membrane was incubated overnight at 4° C in 10 ml 2% nonfat milk powder in TBST (250mM 
Tris pH 8, 1.25M NaCl and 0.1% Tween 20).  The following day, either primary antibody α-
LexA-HRP (used for “bait” proteins)(Santa Cruz) or α-HA (used for “prey” proteins)(Sigma) 
was diluted 1:1000 or 1:1500, respectively, in 5 ml 2% milk and used to incubate the membrane 
for 4 hours at room temperature.  Before incubating with the secondary AB the membrane was 
washed in TBST for 5 minutes, and this was repeated 5 times.  Secondary antibody Goat-α-
rabbit-HRP (Cappel) was used when analyzing prey proteins at a 1:15000 dilution. When 
analyzing bait proteins, no secondary AB was used because the primary AB already contained 
the HRP tag.  Secondary AB, when appropriate, was diluted in 2% milk and incubated with 
membrane for 1 hour.  The membrane was washed in TBST for 5 minutes, and this was repeated 
5 times.  This was followed by two 5 minute washes in TBS (250mM Tris pH 8, 1.25M NaCl).  





2.3 Screening Melanocyte Library 
2.3a Yeast Two Hybrid: Interaction of Melanocyte Library 
The yeast strain EGY48 was used as the host yeast strain for all two-hybrid interaction 
experiments.  This yeast strain has an integrated LEU reporter gene with an upstream LexA 
operator, a pSH18-34 plasmid with an upstream LexA operator, and a LacZ reporter that directs 
the synthesis of β-galactosidase (50).  Special shuttle vectors are used to clone the bait and prey.  
The melanocyte library was previously cloned in pJG4-5 (Zervos lab), which contains a 
galactose inducible promoter.  While the bait proteins Omi (Zervos lab), OmiPDZ (Zervos lab), 
OmiCAT, and L56156-480 were cloned into pGILDA, which also contains a galactose inducible 
promoter.  The pGILDA vector is used for any bait, in this case Omi, whose continuous presence 
is toxic to the yeast (50).  Positive interactions between bait and prey were detected by the 



















Figure 8: Yeast Plasmids:  Map of pSH18-34, pJG4-5, and pGILDA Vectors  
All vectors have a 2µ origin of replication in addition to Ampicillin resistance (AmpR).  A 
selectable marker is present to select for each plasmid when grown in yeast: URA3, TRP1, and 




2.3b High Efficiency Yeast Transformation 
A single yeast colony, EGY48 pSH18-34 pGilda-Omi134-458, was picked and grown 
overnight at 30°C, with shaking, in 50 ml of U- H- Glu drop out medium.  The next day the 
culture was diluted to 300ml with the same medium and grown to an OD600nm of 0.9.  Cells were 
harvested by centrifugation at 3800 rpm for 5 min.  Supernatant was discarded and the cells were 
resuspended in 20ml of sterile H2O. Spin was repeated for 5 min 3800 rpm, and supernatant 
discarded.  Cells were resuspended in 20ml LA (0.1 M LiAc in TE) and spun again for 5 
minutes. Lastly, the cells were resuspended in 5ml of LA.  100µl of competent yeast was 
aliquoted into sterile eppendorf tubes and the following was added: 10µg DNA melanocyte 
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library, 100µg of denatured salmon sperm DNA (carrier DNA), and 600µl of freshly prepared 
40% PEG solution (50% PEG 4000 prepared in water then freshly diluted to 40% in LA 
solution).  The mixture was resuspended, making sure the solution was homogeneous.  The 
transformation reaction was incubated in a 30ºC water bath for 30 min, and then heat-shocked at 
42ºC in water bath for 15 min.  Transformed yeast were centrifuged for 30 seconds, the 
supernatant removed, and pellet resuspended in 500µl of sterile H2O. 300µl of resuspended yeast 
was plated on 24 x 24 cm (Nalge Nunc) U-H-W- Glu selective plates using glass beads (Fisher) 
and incubate at 30°C for two days. 
 
2.3c Aliquoting Library 
The number of colonies in a 2 x 2cm square was counted on 3 sample plates.  An average 
for the squares is obtained and multiplied with 126.6 (the number of 2x2 cm squares in one large 
plate).  This value is the average number of colonies per large plate.  The plates are then placed 
at 4°C so that the agar will harden.  Using autoclaved glass slides and aseptic technique, the 
colonies were scraped from the 10 plates and placed in a Falcon tube.  Each plate was washed 
two times with 10ml of sterile autoclaved water.  The yeast were resuspended and distributed 
evenly into 50ml Falcon tubes.  Next, the yeast were centrifuged at 3800 rpm for 5 minutes.  The 
supernatant was discarded and the pellet was washed with 50ml sterile H2O, and centrifuged 
again for 5 minutes.  This wash was repeated again.  Lastly, the pellet was resuspended, in a 
volume equal to the size of the pellet, in filtered yeast freezing medium (65%glycerol, 0.1M 
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MgSO4, 25 mM Tris, pH 7.4).  The mixture was then aliquoted into small centrifuge tubes at 
300µl each and placed in -80°C.  
 
2.3d Titration 
100µl of thawed “frozen melanocyte library” was grown in 5ml U-H-W- Gal/Raf for 5 
hours at 30°C with shaking.  Serial dilutions of this yeast culture are then prepared as follows: 
Tube 1=100 µl from yeast solution in 900µl of sterile H2O  -->1:500 
Tube 2=100 µl from Tube 1 in 900µl of sterile H2O             -->1:5,000 
Tube 3=100 µl from Tube 2 in 900µl of sterile H2O             -->1:50,000 
Tube 4=100 µl from Tube 3 in 900µl of sterile H2O             -->1:500,000 
Tube 5=100 µl from Tube 4 in 900µl of sterile H2O             -->1:5,000,000 
100µl from each tube was then plated on U-H-W- Gal/Raf plates, and grown for two days 
at 30°C.  Then the colonies from plates 3-5 were counted and multiplied by the dilution factor.  
This is done to determine the amount needed to be plated on a large U-H-W-L- Gal/Raf plate in 
order to yield the correct number of colonies that will represent the entire library.  This 





After growth selection was performed on U-H-W-L- Gal/Raf, the positive colonies were 
then streaked onto U-H-W- Glu plates, and grown for two days at 37°C.  Next, the colonies were 
streaked onto U-H-W- Glu/X-Gal and U-H-W- Gal/Raf/X-Gal plates.  For color selection, positive 
interactions between bait and prey were detected by the presence of blue colonies on the U-H-W- 
Gal/Raf/X-Gal plates and these were inoculated in U-H-W- Glu medium to select for the pJG4-5 
melanocyte library plasmid.  These were grown overnight at 30°C with shaking to release the 
plasmid from yeast. 
 
2.3f Release plasmid from Yeast 
A single yeast colony was picked with a sterile toothpick and grown in 1ml U-H-W-Glu 
medium overnight.  Then, the culture was transferred to a screw cap microcentrifuge tube. The 
yeast was centrifuged for 1 minute at 14,000 rpm.  The pellet was resuspended in 200µl of yeast 
lysis solution (2% TritonX-100, 1% SDS, 100mM NaCl, 10mM Tris pH 8.0, 1mM EDTA).  
Approximately 0.3 g of glass beads (Sigma) was added to assist in the lysis along with 200µl of 
Phenol-chloroform-isoamyl alcohol (25:24:1). The tube was capped and vortexed vigorously for 
2 minutes or until the mixture became homogenous.  The tube was centrifuged for 2 minutes to 
separate the phases, and the upper aqueous phase was transferred to a new microcentrifuge tube. 
DNA was precipitated as described in section 2.1d. 
 34
 
2.3g Transformation of Plasmid into KC8 
The plasmids extracted from the yeast were transformed into KC8 bacterial cells using 
the transformation protocol in section 2.1g. 
 
2.3h Sequencing of Melanocye Library Positive Interactors 
Positive clones were extracted from KC8 bacterial cells using the miniprep protocol in 
section 2.1h.  These plasmids were then sequenced to identify the clone using the protocol in 
section 2.1j. 
 
2.3i Retransformation in Yeast 
The positive interactors for Omi134-458 were retransformed into yeast containing pGILDA-
Omi134-458, pGILDA-OmiPDZ, pGILDA-OmiCAT, pGILDA-L56 using the yeast transformation 
protocol in section 2.2a. 
 
2.4 Construction of pJG4-5-HOPS and GFP-HOPS 
2.4a Polymerase Chain Reaction 
The following primers were used in the PCR reaction for the cloning of pJG4-5-HOPS 
and pGFP-HOPS. 
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Primer E 5’ pJG4-5-HOPS (EcoRI) 
5’- CGG AAT TCA TGT TAA CTC TTA ATC TAG TTA AAC – 3’ 
Primer F 5’ pJG4-5-HOPS (EcoRI) 
5’ – CGG AAT TCT ATG TTA ACT CTT AAT CTA GTT AAA C – 3’ 
Primer G 3’ pGFP-HOPS and pJG4-5-HOPS (SalI) 
5’ – GCC GAC GTC GAC CTA TAT CAT AGT GAC TTC ATA TG-3’ 
The restriction sites incorporated into each primer XhoI and SalI are underlined.  The 
PCR products were then digested with the appropriate enzyme and cloned into either pEGFP-C1 










          
 
Figure 9: Maps of pEGFP-C1 and pET-28a Vectors 
(A) Map of pEGFP-C1 vector used in localization experiments (figure taken from: 
www.clontech.com).  (B) Map of pET-28a vector used in protein expression experiment (figure 
taken from: http://www.emdbiosciences.com/html/NVG/AllTables.html). 
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2.5 Cleavage Assay 
2.5a TNT 
The following primer was used in the PCR reaction for the TNT reaction of pJG4-5-
HOPS: 
Primer K 5’ pJG4-5 with T7 promoter and Kozak sequence 
5’-TAA TAC GAC TCA CTA TAG GGG ACG ACC ATG GTG CCA GAT TAT GCC 
TCT CCC-3’ 
Primer L 3’ pJG4-5 
The PCR reaction was performed following the protocol in section 2.1a. 
The general protocol for a 50µl TNT reaction is as follows: 
TNT T7 Quick Master Mix (Promega)       40µl 
[35S] methionine/cysteine (1,000Ci/mmol at 10mCi/ml) (Promega)                 2µl 
PCR generated DNA template                                                 2.5-5µl 
H2O                         3-5.5 µl 
The reaction is incubated at 30˚C for 1.5 hours 
 
2.5b Degradation Assay 
The product of the TNT reaction was incubated with mature his-tag purified Omi134-458 as 
shown in Table 1.  The reaction was performed in a final volume of 20µl. 
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Table 1: Description of Cleavage Assay 
+ve -ve 
[S35]-HOPS                                       
5µl 
[S35]-HOPS                                        
5µl 
Omi 134-458                                           
5µl 
Omi134-458                                            
0µl
Omi Assay Buffer                             
10µl 
Omi Assay Buffer                              
15µl 
 
The mixture was incubated at 37˚C for 1 hour.  10µl of 2X sample loading buffer was 




2.6 Transfection in Hela Cells 
2.6a Growing HeLa Cells 
HeLa cells, human cervical carcinoma cell line, were grown using F12-Nutrient Mixture 
(HAM) media (Life Technologies) supplemented with 10% FCS (Sigma), 2mM L-glutamine, 
100U/ml penicillin and 100µg/ml streptomycin (Life technologies).  
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2.6b Transfections and Immunofluorescence Microscopy 
For immunofluorescence, the cells were grown on cover-slips.  Approximately 70% 
confluent cells were transfected with 2µg of pEGFP-HOPS using Lipofectamine Plus reagent 
according to the instructions provided by the manufacturer (Life Technologies).  After 24 hours, 
the transfected cells were washed 3 times with PBS and fixed with 4% paraformaldehyde.  The 
cover-slips were then placed on glass slides using Fluoromount-G solution (Southern 
Biochemical Association).  The subcellular localization of GFP fusion proteins was monitored 
using a LSM510 confocal laser-scanning microscope (Carl Zeiss). 
 
 
2.7 Transfection in 293T Cells 
2.7a Growing 293T Cells 
293T cells, human fibroblast cells, were grown using DMEM  media (Life Technologies) 
supplemented with 10% FCS (Sigma), 2mM L-glutamine, 100U/ml penicillin and 100µg/ml 




2.7b Induction of Apoptosis 
HEK-293T cells were transfected with either GFP-HOPS or DsRED-Omi134-458 using 
Lipofectamin Plus reagent according to the manufacturers directions (Life Technologies).  The 
following morning the medium was removed.   Fresh 293T medium was treated with either 
2mmol H2O2 or 2mmol Cisplatin.  The new medium was added to the cells and 12 hours after 
treatment the cells were analyzed.     
 
2.7c Western Blot of Mammalian Cells  
Twelve hours after treatment the cells were recovered by pipetting, and placed in a 2ml 
microcentrifuge tube.   The wells were washed with 500µl of PBS.  The tubes are spun at 3500-
4000 rpm for 3 minutes.  The supernatant is aspirated.  The pellet is resuspended in 150µl of 
lysis buffer (1%Triton-X-100, 10%glycerol, 150mM NaCl, 20mM Tris pH7.5, 2mM EDTA, 
protease inhibitor cocktail SIGMA).   The mixture is then placed in ice for 10 minutes.  The cells 
are then lysed using a combination of freezing with dry ice for 2 minutes and then thawing the 
cells at 37˚C for 1 minute.  This process is repeated five times with a 30 second vortexing 
between each repeat.  The cells are spun at 4˚C and 14000rpm for 10 minutes.  The supernatant 
is then transferred to a new tube and the protein concentration is measured for equal loading 




2.8 Purification of HOPS133-233
2.8a Transformation of BL21  
  BL21 expression bacteria are used to for protein purification.  The bacteria are 
transformed using 1µl of DNA from a 1:10 dilution of clean miniprep DNA, following the 
protocol in section 2.1g. 
 
2.8b Protein Purification 
BL21 bacteria transformed with pET28a-HOPS133-233   were grown O/N in the appropriate 
LB containing Kanamycin.  The following morning the bacteria were placed in the appropriate 
volume of medium with 50µg/ml.  The culture was grown at 250rpm and 37˚C to an OD600 of 
0.8.  1ml of bacteria was obtained before induction for analysis.  The temperature was then 
dropped to 25˚C and induction was performed using 1mM IPTG.  Induction was done O/N.  The 
following morning 1ml of bacteria is obtained for analysis, and the remaining culture is spun at 
6000rpm and 4˚C for 10 minutes.  The supernatant is discarded and the pellet is placed on ice.  
The pellet was resuspended in 25-40ml of Lysis Buffer which is composed of Binding Buffer + 
4X Protease Inhibitor Cocktail (SIGMA) diluted to a concentration of 1:100.  This mixture was 
placed in a 50ml Falcon tube and lyzozyme (10mg/ml) is added 1:100; the mixture was placed at 
30˚C for 15 minutes.  1% Triton X-100 was added and the solution was spun at room 
temperature for one hour.  The cells are then sonicated 3 times, each time for one minute and 
then they were placed on ice for 1 minute.  The mixture was then centrifuged at 4˚C 13000rpm 
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for 30 minutes.  The supernatant was filtered with .45micron filter and 4ml of 50% Ni-NTA 
beads were added.  This was mixed O/N at 4˚C.  The next morning everything was placed in a 
column and the flow through was collected for analysis.  The column was washed 2 times with 
50ml of 1X Binding Buffer (8X=400mM NaH2PO4, 2.4M NaCl, 80mM Imidazole, 0.4% NaN3).  
Then the column was washed 2 times with 50ml of 1X Wash Buffer (8X=400mM NaH2PO4, 
2.4M NaCl, 160mM Imidazole, 0.4% NaN3).  The column is then eluted 2 times with 2ml of 
Elution Buffer (4X=200mM NaH2PO4, 1.2M NaCl, 1M Imidazole, 0.2% NaN3).  The eluant was 
then dialysed in Dialysis Buffer (40mM Hepes and 200mM NaCl).  The purified protein was 
then subjected to SDS-PAGE to analyze purity. 
 
 
2.9 Regulation Assay 
2.9a Regulation Assay 
Purified HIS-HOPS133-233 was incubated with either his-tag purified mature Omi134-458 or 
his-tag purified inactive OmiS-C276 protein to see if HOPS133-233 has a regulatory role on the 
protease activity of Omi. HOPS133-233 was incubated together with either Omi134-458 or OmiS-C276 
for 10 minutes.  2µl of 2.5mg/ml β-casein was then added to the mixture.  The final reaction 
volume of 20µl was reached using Omi Assay Buffer (20mM NaH2PO4/Na2HPO4, pH 7.4, 
200mM NaCl, 5% Glycerol).  The samples were loaded side by side on a 12% SDS-PAGE and 
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the gel was stained with Coomassie for 3 hours and destained with Destaining Solution 
(20%Methanol, 10% Acetic Acid) overnight. 
CHAPTER THREE: RESULTS 
3.1 Cloning and Yeast Expression of LexA-Omi134-340 and LexA-L56157-485 
DNA corresponding to the mature form of Omi134-458 protein, the catalytic domain (amino 
acids 134-340) or the PDZ domain (amino acids 340-458) was cloned into the pGILDA yeast 
expression vector.  Using these three different baits, one could assess which domain of Omi a 
potential interactor was binding. 
In addition, as a control, DNA for the HtrA1/L56157-480 protein was also cloned into the 
pGILDA vector.  Since Omi and L56 share high sequence homology, this protein will be used to 
determine the specificity of any interactors. 
The catalytic domains of Omi and L56157-480 were expressed as Lex-A (DNA binding 
domain) fusion proteins using the pGILDA vector as described in Materials and Methods.  
Transcription of these bait proteins is under the control of a GAL1 promoter, and therefore are 
only expressed in yeast in the presence of galactose.  These constructs were transformed into 
yeast cells and expression of the recombinant LexA-fusion proteins was monitored by Western 
Blot analysis of yeast whole cell extracts grown either in glucose or galactose.  
LexA- Omi134-340 has an estimated molecular weight of ≈43 kDa, which corresponds to 
the estimated molecular weight of the catalytic domain, 23kDa fused with the LexA DNA-
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binding domain, ≈20kDa (Figure 10). LexA- L56157-480 has an estimated molecular weight of 56 
kDa, which corresponds to the estimated molecular weight of L56157-480, ≈36kDa, fused with 




















Figure 10: Cloning and Yeast Expression of pGILDAOmi134-340
Yeast-expression of various baits in the presence of glucose or galactose.  Lane 1: LexA-Omi134-
458 glucose; Lane 2: LexA-Omi134-458 galactose; Lane 3: LexA-Omi134-340 glucose; Lane 4: LexA-
Omi134-340 galactose. 





Figure 11: Cloning and Yeast Expression of pGilda-L56157-480
Expression of LexA-L56157-480 in the presence of glucose or galactose. 
Lane 1: LexA-L56157-480 glucose; Lane 2: LexA-L56157-480 galactose; Lane 3: LexA-Omi134-458 




3.2 Screening the Melanocyte cDNA Library 
RNA was obtained from cultured, actively growing, human melanocyte cells.  This RNA 
was used to make cDNAs, which was then cloned unidirectionally as an EcoR1/Xho1 fragment 
into the corresponding sites of the pJG4-5 vector (Zervos Lab).  This melanocyte cDNA library 
was used in the yeast two hybrid screening. 
The mature form of Omi134-458 fused to LexA was used as the bait in this screening.  
Additionally, two reporter genes, the LexAop-LEU2 gene allowing the growth of the colonies in 
the absence of leucine and the LexAop-lacZ gene that directs the synthesis of β-galactosidase, 
were included.  The number of clones per plate was estimated by counting the number of 
colonies in a 2x2 cm squares.  Two squares were counted on each of the ten plates, averaged, and 
then extrapolated to estimate the number of clones per plate.  A total of 7X105 colonies were 
present. 
7 million primary yeast colonies were screened for cDNAs encoding proteins that 
potentially interact with the mature form of Omi.  Of these seven million colonies 100 colonies 
were initially identified by their ability to grow on U-H-W-L- Galactose selective plates.  These 
were then tested on U-H-W- Glucose/X-Gal and U-H-W- Galactose/X-Gal plates.  Fifty-one of 
them were found to have a galactose dependent phenotype.  Twenty-five of the colonies were 
identified as false positives, correlating to either a blue colony on U-H-W- Glucose/X-Gal that 
could not be further examined, or a white colony on U-H-W- Galactose/X-Gal that suggests no 









                        U-H-W- Glucose/X-Gal                     U-H-W- Galactose/X-Gal 
 
 
Figure 12: Melanocyte cDNA Library Screening 
A positive interaction between the bait protein and the prey protein, leads to blue colonies on U-
H-W- Galactose/X-Gal.  White colonies suggest a negative protein-protein interaction.  Blue 





3.3 Characterization of Omi Interactors 
The cDNA library plasmids, were rescued from each of the positive yeast clones, and 
introduced into KC8 bacteria by electroporation.  The prey plasmids were then isolated using a 
Miniprep Kit (QIAGEN).  The cDNAs were sequenced, and homology searches were performed 
using the BLAST program provided by on the NCBI server (www.ncbi.nlm.nih.gov/BLAST/). 
Screening in yeast was repeated using these 51 purified cDNA library plasmid as “prey” and 
either LexA-Omi134-458, LexA-OmiCAT134-340, LexA-OmiPDZ340-458, or LexA-L56157-480 as the 
“bait”.   
The results of the yeast transformation revealed that of the 51 positive clones, 32 were 
true positives. A positive interaction, resulting in a blue colony on U-H-W- Galactose/ X-Gal, 
between one of the bait proteins (LexA- Omi134-458, LexA- OmiCAT134-340, LexA- OmiPDZ340-458, 
and LexA- L56157-480) and the prey (interactors identified in melanocyte library cDNA screening) 
corresponds to a + on the chart.  However, a negative interaction yielding no color change, 
corresponds to a – on the table.  These 32 interactors were sequenced and 17 distinct family 
proteins were identified.  Each isolated cDNA is a true interactor of Omi, however, these 
interactors may be localized in a different location then Omi under normal physiological 
conditions.  This localization must be taken into consideration when choosing a particular 
intereactor to characterize.  There must be a possiblility that Omi is able to encounter the 
interactor under normal conditions.  One of these interactors we call HOPS, for HtrA/Omi 
protein substrate, was selected for further characterization.   
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Table 2: List of Omi Interactors Isolated From a Human Melanocyte cDNA Library 
NAME Omi134-458 OmiCAT134-340 OmiPDZ340-458 L56157-480
Thyroid receptor 
interacting protein 15 
+ - - + 
Complement component 
1, q subcomponent/ p32 
+ - + - 
Macrophage migration 
inhibitory factor 
+ - + + 
D-dopachrome 
tautomerase 
+ + + + 
Nucleostemin + + + + 
HOPS + - + + 
Protein kinase c like 2 + - + - 
Protein kinase c substrate 
80K-H 
+ + + - 
Homo sapiens glutatione-
s-transferase omega 2 
+ + + - 
SCAP2 + + + + 
Collagen type 11 + + + - 
Glutamate dehydrogenase 
1 
+ + + - 
Homo sapiens calcium 
binding protein Cab 45 
precursor 
+ + + + 
Scaffold Attachment 
Factor B 
+ - + - 
Crystallin, lambda 1 + + + + 
Supressor of Ty 4 
homolog 
+ + + - 
Laminin receptor 1 + - + - 
 
A positive protein-protein interaction is represented by a +, while no protein-protein interaction 
corresponds to a -.   
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3.4 Characterization of HOPS 
The HOPS protein was isolated twice of the 32 positive clones as a true positive 
interactor of LexA-Omi134-458 in the melanocyte library screening.  This protein is a novel protein 
of unknown function.  HOPS is located at chromosome 7q22.3.  Using the PSORT II program, 
HOPS, the protein is predicted to localize in either the nucleus or mitochondria.   
 
 
Figure 13: Sequence of HOPS   
Nucleotide and amino acid sequence of HOPS.  The C-terminal portion underlined in red 
represents the clone obtained in the melanocyte library screening.   
 51






B. Transcript Structure 
 
                            
 
 
Figure 14: Genomic Structure of HOPS   
(A) The gene is mapped to chromosome 7q22.3.   (B) The transcript structure of HOPS.  The 
gene contains three exons and two introns. Coding sequence is exclusively derived from Exon I.   


















Figure 15: Alignment of Human HOPS with Mouse and Chicken Orthologues 
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Figure 16: Homology Search 
A BLAST search against full length HOPS identifies three other cDNAs with limited homology.  
1. HOPS. 
2. Similar to THAP domain containing 5 protein [Homo sapiens].  
3. Unnamed protein product [Tetraodon nigroviridis]. 
















Head normal 1.51 
Kidney 3.03 
Lymph 1.51 
Muscle (skeletal) 1.51 
Hippocampus 1.51 
Medulla 3.03 
Frontal lobe 3.03 
White matter 1.51 
Total fetus 3.03 
Fetal brain 4.54 
Embryonic stem cell DMSO treated H9 cell line 1.51 
Embryonic stem cell treated H1, H7, H9 retina 3.03 
Embryonic stem cell retinoic acid and mitogenic hES cell line H7 1.51 
Colon tumor RER 1.51 
Embryonal carcinoma 3.03 
Nervous tumor 3.03 




Acute myelogenous leukemia 1.51 
Chronic myelogenous leukemia 1.51 
Moderately differentiated adenocarcinoma 1.51 
Adenocarcinoma 1.51 
Hypernephroma cell line 1.51 
Duodenal adenocarcinoma cell line 1.51 
Transitional cell papilloma cell line 1.51 
Mammary adenocarcinoma cell line 1.51 
Human chondrosarcoma cell line 1.51 
Mixed 1.51 
Pooled 3.03 
2 pooled wilms tumors: one primary and one metastatic to brain 1.51 
Pooled lung and spleen 1.51 
2 pooled tumors clear type 1.51 
Three pooled meningiomas 1.51 
The various tissue distributions of known ESTs for HOPS suggest a wide expression of this 
gene.  The highest expression is seen in the brain and ectodermally derived organs, as well as 
cancer cells. 
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3.5 Expression of full-length HOPS protein in Yeast 
The full-length cDNA clone of HOPS in the pCMV-SPORT6 vector was obtained (Open 
Biosystems I.M.A.G.E. Consortium).  PCR was used to prepare DNA corresponding to the 
complete coding sequence using the primers described in Materials and Methods.  HOPS full-
length cDNA was cloned in frame with the B42 activation domain and HA-tag in the pJG4-5 
vector.  This prey protein, under the control of a GAL1 promoter, is expressed in yeast only in 
the presence of galactose.  Whole cell extracts of the transformed yeast grown in either the 
presence of glucose or galactose, were subjected to SDS-PAGE.   The expression of this B42 
fusion protein was monitored by Western Blot analysis using HA-antibodies (ROCHE).  The 
HOPS protein can be observed as a band at ≈36 kDa, this corresponds to the estimated molecular 














Figure 17: HOPS Expression in Yeast 
Expression of HOPS133-233 and full length HOPS protein in the presence of glucose or galactose.  
Equal amounts of yeast lysates were subjected to SDS-PAGE followed by Western Blot analysis 
using anti-HA primary antibody followed by goat-anti-mouse secondary antibody.  Lane 1: 





3.6 Interaction of Full-length HOPS Protein With Various Baits in Yeast 
The full-length HOPS protein was expressed as a prey in a yeast strain EGY48 along 
with one of the following bait proteins: LexA-Omi134-458, LexA-OmiCAT134-340, LexA-OmiPDZ340-
458, LexA-L56157-480.  The full-length protein interacted with both the mature form of Omi134-458 
as well as the OmiPDZ340-458.  However, unlike the partial HOPS clone originally isolated from the 









































Figure 18: Specificity of the Partial HOPS Clone in Yeast  
HOPS137-233 was used as a prey against the following baits: LexA-Omi134-458, LexA-OmiCAT134-
340, LexA-OmiPDZ340-458, LexA-L56157-480.  HOPS137-233 is shown to interact with L56 as well as 
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Yeast colonies were transformed with the indicated bait and the full-length HOPS prey.  A blue 
colony represents a positive protein-protein interaction, while white colonies indicate no 




3.7 Degradation Assay  
I investigated the possibility that Omi, a serine protease, might be able to degrade HOPS 
protein in vitro. [S35]-labeled HOPS was used as a potential substrate against bacterially made 
Omi134-458 in an in vitro assay as described (Materials and Methods) Briefly, His-Omi134-458 was 
incubated with the [S35]-HOPS in 20µl final reaction volume at 37˚C for 1 hour.  The products 
were subjected to SDS-PAGE and then observed by autoradiography.  
 In the presence of Omi134-458, HOPS was cleaved.  After degradation, HOPS can 
be seen as a band of ≈36kDa and a new peptide band appears between 25kDa and 32kDa (Figure 
20). 
 
Figure 20: HOPS is Cleaved by Omi In Vitro 
Lane 1: [S35]-HOPS; Lane 2: [S35]-HOPS + His-Omi134-458. 
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3.8 Subcellular Localization of HOPS 
The full-length HOPS protein was expressed as a fusion to green fluorescent protein 
using the pEGFP-C1 (Clontech) mammalian expression vector as described (Materials and 
Methods).  This construct was co-transfected into HeLa cells with DsRed-Omi134-458.  The 
pDsRed1-C1 vector (Clontech) fuses a red florescence protein to the C-terminus of Omi.  The 
HeLa cells were grown on a cover slip and 24 hours after transfection were fixed on the slide so 
that the fluorescent proteins could be observed using a confocal microscope.  The subcellular 
localization of the fluorescent fusion proteins was observed (Figure 21). 
 
.  
Figure 21: Co-localization of GFP-HOPS137-233 and DsRED-Omi134-458  
             A                             B                           C                            D 
HeLa cells were transiently co-transfected with both GFP-HOPS137-233 (A) and DsRED-Omi134-
458 (B).  After transfection the cells were fixed and examined by confocal microscopy.  Merged 




3.9 GFP-HOPS is Cleaved in Mammalian Cells in Response Cisplatin Treatment 
 
293T cells were transfected with pEGFP-HOPS as described in Materials and Methods.  
The cells were treated with either H2O2 or Cisplatin for twelve hours.  Equal amounts of whole 
cell extracts were subjected to SDS-PAGE and the protein level of GFP-HOPS was monitored by 
Western blot analysis using anti-GFP monoclonal antibodies, followed by goat-anti-mouse 
secondary antibody.  GFP-HOPS can be seen as a band at ≈54 kDa, which corresponds to the 
estimated molecular weight of HOPS, ≈25kDa, and GFP, ≈29 kDa.  In Figure 22, it can be seen 
that in the presence of Cisplatin the concentration of HOPS decreases.  Equal loading was 















































Figure 22: GFP-HOPS is Degraded in Mammalian Cells after Cisplatin Treatment.   
(A) Degradation of GFP-HOPS proteins was monitored by Western Blot analysis.  Equal 
amounts of whole cell lysates prepared from cells treated with H2O2or Cisplatin were subjected 
to SDS-PAGE followed by Western Blot analysis using anti-GFP primary antibody followed by 
anti-mouse secondary antibody.  Lane 1: GFP-HOPS; Lane 2: GFP-HOPS + H2O2; Lane 3: GFP-
HOPS + Cisplatin. (B) To verify equal amounts of protein was used in each lane the blot from A 
was probed with β-actin antibodies.  
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3.10 Expression and Purification of HOPS133-233 in Bacteria 
PCR was used to amplify DNA corresponding to HOPS C-terminal (amino acids 137-
233) domain and cloned into the pET-28A vector as described (Materials and Methods).  The 
pET28A vector allows proteins to be expressed as fusions with a 6-His-tag.  The construct was 
then transformed by electroporation into BL21 bacteria.  Recombinant protein was purified using 
native-state conditions and Ni-NTA beads.  The purified recombinant HOPS133-233 protein was 
analyzed by SDS-PAGE stained with Coomassie Blue dye.  C-terminal HOPS137-233 can be seen 



























Figure 23: Expression and Purification of Recombinant His-HOPS133-233 Protein 
His-HOPS133-233 was expressed in BL21 expression strain bacteria.  Lane1: Marker; Lane 2: 
empty; Lane 3,5, 7, 9: whole cell lysates of BL21containing His-HOPS133-233 not induced; Lane 
4, 6, 8, 10: whole cell lysates of BL21 containing His-HOPS133-233 induced with IPTG.   
(B) His-HOPS133-233 was purified from BL21 using Ni-NTA beads.  Lane 1: Marker; Lane 2 and 
Lane 3: BL21 whole cell lysate not induced; Lane 4: BL21 whole cell lysate induced with IPTG; 
Lane 5: 5µl purified His-HOPS133-233 elution 2; Lane 6: 10µl purified HOPS elution 2; Lane 7: 
15µl purified His-HOPS133-233 elution 2; Lane 8: 15µl purified His-HOPS133-233 elution 1 
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3.11 Potential Regulation of Omi’s Proteolytic Activity by Recombinant 
HOPS133-233 Protein 
The purified His-HOPS133-233 protein was incubated with bacterially made Omi134-458 in 
the presence of β-casein, a generic substrate for Omi.  The results shown in Figure 24 suggest 
that the C-terminus of HOPS133-233 has no regulatory control over Omi’s proteolytic activity 
when tested against β-casein. 
 
 







Figure 24: HOPS133-233 Effect on the Proteolytic Activity of Omi In Vitro  
HOPS133-233 does not affect the proteolytic activity of Omi in vitro.  His-HOPS133-233 was 
incubated with His-Omi134-458 in the presence of β-casein.  Lane 1: Marker; Lane 2 β-casein; 
Lane 3: β-casein + His-Omi134-458; Lane 4: β-casein + His- Omi134-458 + His-HOPS133-233; Lane 5: 
His-Omi134-458 + His-HOPS133-233; Lane 6: His- HOPS133-233. 
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3.12 Bacterially Expressed HOPS133-233 is Degraded In Vitro by Omi134-458
The purified His-HOPS133-233 protein was incubated with bacterially made Omi134-
458 over a time course of 24 hours.  Figure 24 shows that even at 4 hours of incubation 






Figure 25: HOPS133-233 is Degraded by Omi134-458 In Vitro 
Lane 1: Molecular Weight marker; Lane 2: His-HOPS133-233 alone; Lane 3: His-Omi134-458+His- 
Omi134-458 1 hour incubation; Lane 4: His-Omi134-458+His- Omi134-458 2 hour incubation; Lane 5: 
His-Omi134-458+His- Omi134-458 3 hour incubation; Lane 6: His-Omi134-458+His- Omi134-458 4 hour 
incubation: Lane 7: His-Omi134-458+His- Omi134-458 8 hour incubation; Lane 8: His-Omi134-








CHAPTER FOUR: DISCUSSION 
Omi/HtrA2 is a serine protease belonging to the HtrA family of proteins and is highly 
conserved throughout different species.  Omi protein shares homology with the bacterially 
expressed heat shock protease HtrA, that functions as a protease at higher temperatures and a 
chaperone at lower temperatures (31).  Additionally, Omi shares sequence similarity with the 
mammalian homologs L56/HtrA1 and PRSP/HtrA3 (31, 34).  However, this homology with Omi 
lies largely at the carboxy-terminus.  Omi possesses a different amino-terminus which contains a 
regulatory domain not seen in the other two human homologs (34).   
Omi has a series of functional domains including an amino-terminal regulatory domain, a 
catalytic domain, and a PDZ domain.  The regulatory domain contains a mitochondrial targeting 
sequence (MTS), a predicted transmembrane region, a phosphorylation site, and an SH3-binding 
domain (28, 33).  In the mature form of Omi, the MTS is removed, revealing a conserved IAP-
binding motif, AVPS, at the new amino-terminus (29).  The conserved catalytic domain has 
extensive similarity to serine proteases, such as trypsin, and is involved in the cleavage and 
degradation of substrates such as XIAP (35).  In accord with other PDZ domains, including those 
of the bacterial HtrA, the PDZ domain of Omi is assumed to be involved in protein-protein 
interactions (44).  
Omi has been identified as an active participant in both the caspase-dependent as well as 
caspase-independent pathways of cell death (28, 29, 44). In the caspase-dependent pathway, Omi 
binds and degrades IAPs, thus allowing apoptosis to proceed.  This is accomplished by two 
mechanisms.  First, by binding to IAPs through its N-terminal AVPS motif, hindering their 
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ability to bind to caspases (46).  Secondly, Omi cleaves and irreversibly removes IAPs through 
its proteolytic activity (29, 36, 44, 47, 48).  Omi is also involved in the caspase-independent 
pathway, but the mechanism remains unclear. The proteolytic activity of Omi is necessary and 
essential for this “atypical” cell death, and does not involve interaction with IAPs (28, 44).   
Recent studies have revealed Omi has yet another unique function in mitochondria (12).  
A missense mutation of Omi was identified in Mnd2 mice, which reduces the protease activity of 
the protein.  This mutation results in a neurodegenerative phenotype rather than the excessive 
cell proliferation one would expect if Omi’s sole function were to induce apoptosis.  This 
suggests that perhaps the primary function of Omi in mammalian cells deals with the 
maintenance of mitochondrial homeostasis, and resembling its bacterial homolog, functions as a 
chaperone (45). 
Omi was first isolated as an interacting protein of Mxi2, an alternatively spliced form of 
the p38 stress-activated kinase, using a modified yeast two-hybrid system.  The PDZ domain of 
Omi specifically recognizes the carboxy-terminus of Mxi2 (31).  To date, there are several 
known interactors of Omi including the Mxi2, XIAP, cIAP1, the newly identified protein HAX1, 
and Presenilin1 (29, 31, 46).  XIAP, cIAP and HAX 1 proteins are Omi substrates whose 
activation augments cell death. Presenilin1 has recently been shown to boast a different function; 
upon interacting with Omi, Presenilin 1 regulates its serine protease activity.  A synthetic peptide 
encompassing the last 15 carboxy-terminal amino acids of Presenilin 1 is also able to 
substantially increase the proteolytic activity of Omi both in vitro as well as in vivo (51). 
A screening of a primary melanocyte cDNA library was performed to isolate novel 
interacting proteins that may further elucidate the function of Omi.  This cDNA library was 
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selected under the assumption that, unlike a cancer cell line, primary cells, such as the 
melanocytes used here, would have their apoptotic pathway intact and express a range of pro-
apoptotic and anti-apoptotic proteins.  Upon screening the cDNA library, a novel protein HOPS 
was identified.  The isolated partial cDNA of HOPS contained the last 100 amino acids of the 
protein.  This partial protein was shown to interact with the mature form of Omi, the PDZ 
domain of Omi, as well as the mature form of L56 in yeast two hybrid experiments.  However, 
when the full length HOPS protein was tested in the same assay the results were even more 
promising showing that full length HOPS is specific for only Omi and its PDZ domain, and no 
longer binds to L56. 
Though extensive sequence analysis of HOPS was performed, not much information was 
obtained that would suggest a potential function for this protein.  HOPS shares sequence 
similarity with only two other proteins.  The first is a hypothetical protein from Homo sapiens, 
DKFZp564I0422, and second is the protein RIKEN of Mus musculus; each contains only 31% 
and 48% sequence similarity, respectively.  Analysis using PSORTII computer software 
suggested that the localization of HOPS was either nuclear (39%) or mitochondrial (30%).  
However, when transfected in HeLa cells the GFP-HOPS fusion proteins was found 
predominantly in the cytoplasm. 
HOPS could be involved in the normal function of Omi under two different scenarios.  In 
the first, HOPS could be a physiological substrate of Omi as is the case with XIAP, cIAP, 
HAX1.  In the second, like the Presenilin 1, HOPS may regulate the serine protease activity of 
Omi.  A degradation assay was performed to test the possibility that HOPS might be a substrate 
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for the Omi.  Mature Omi was incubated with [S35]-HOPS giving rise to one major cleavage 
product.  This suggested the possibility that HOPS could indeed be a substrate of Omi.  
 Since the in vitro study revealed the possibility for cleavage, an in vivo experiment was 
designed to further confirm these results.  GFP-HOPS was transfected in 293T cells and the cells 
were then treated with apoptosis-inducing agents including H2O2 and cisplatin.  In accord with 
the in vitro degradation assay, a decrease in the amount of HOPS protein was observed during 
cisplatin-induced apoptosis.  These results suggest that HOPS could be a physiological substrate 
of Omi that is cleaved and removed during the apoptotic process. 
Both Mxi2 and Presenilin 1 have been shown to interact specifically with the PDZ 
domain of Omi.  PDZ domains are known for their ability to recognize the carboxy- terminus of 
proteins.  Mxi2 ends in the amino acids LTIYPHLMDIELVMI while Presenilin 1 ends with 
VQPFMDQLAFHQFYI.  HOPS has sequence homology with both of these proteins as it ends in 
the following sequence KIIENHFTTYEVTMI.  To ascertain whether or not HOPS alters the 
proteolytic activity of Omi, recombinant carboxy-terminal HOPS was purified from bacteria and 
used in an enzymatic activity assay.  This recombinant HOPS protein encompassed only the last 
100 amino acids. When expressed in bacteria, full length HOPS was insoluble, and therefore 
could not be purified using non-denaturing conditions.  When the C-terminal HOPS was 
incubated with mature Omi in an in vitro assay, no change in the proteolytic activity of the 
enzyme was observed. A generic substrate, β-casein, was used in these experiments.  
 In conclusion, Omi has been shown to interact with a variety of proteins in 
mammalian cells. These proteins can be substrates or regulators of Omi’s proteolytic activity. 
The isolation of HOPS brings us closer to understanding the mechanism of Omi’s normal 
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function. Since the amino acid sequence of HOPS suggests little about its role in the cells, it is 
hard to speculate how its degradation and removal by Omi assists the apoptotic process.  Further 
experiments currently under way in our lab will be used to provide further details on HOPS and 
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